KR20090088878A - 신규한 항증식 항체 - Google Patents

신규한 항증식 항체 Download PDF

Info

Publication number
KR20090088878A
KR20090088878A KR1020097009675A KR20097009675A KR20090088878A KR 20090088878 A KR20090088878 A KR 20090088878A KR 1020097009675 A KR1020097009675 A KR 1020097009675A KR 20097009675 A KR20097009675 A KR 20097009675A KR 20090088878 A KR20090088878 A KR 20090088878A
Authority
KR
South Korea
Prior art keywords
seq
sequence
antibody
cdr
homology
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020097009675A
Other languages
English (en)
Korean (ko)
Inventor
릴리앙 꼬뜨쉬
나딸리 꼬르바이야
쟝-프랑끄와 아오
세드릭 베
Original Assignee
피에르 파브르 메디카먼트
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 피에르 파브르 메디카먼트 filed Critical 피에르 파브르 메디카먼트
Publication of KR20090088878A publication Critical patent/KR20090088878A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
KR1020097009675A 2006-11-24 2007-11-23 신규한 항증식 항체 Ceased KR20090088878A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0610329 2006-11-24
FR0610329A FR2909092B1 (fr) 2006-11-24 2006-11-24 Nouveaux anticorps anti-proliferation

Publications (1)

Publication Number Publication Date
KR20090088878A true KR20090088878A (ko) 2009-08-20

Family

ID=37903981

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020097009675A Ceased KR20090088878A (ko) 2006-11-24 2007-11-23 신규한 항증식 항체

Country Status (27)

Country Link
US (2) US8071730B2 (enExample)
EP (1) EP2074148A1 (enExample)
JP (1) JP2010509931A (enExample)
KR (1) KR20090088878A (enExample)
CN (1) CN101535344B (enExample)
AU (1) AU2007324509B2 (enExample)
BR (1) BRPI0719323A2 (enExample)
CA (1) CA2670039A1 (enExample)
CL (1) CL2007003357A1 (enExample)
CR (1) CR10788A (enExample)
CU (1) CU23792A3 (enExample)
EC (1) ECSP099341A (enExample)
FR (1) FR2909092B1 (enExample)
GE (1) GEP20125629B (enExample)
GT (1) GT200900126A (enExample)
IL (1) IL198744A0 (enExample)
MA (1) MA30891B1 (enExample)
MX (1) MX2009005293A (enExample)
NI (1) NI200900079A (enExample)
NO (1) NO20092360L (enExample)
NZ (1) NZ576174A (enExample)
RU (1) RU2451689C2 (enExample)
SA (1) SA07280637B1 (enExample)
TN (1) TN2009000194A1 (enExample)
TW (1) TW200829602A (enExample)
UA (1) UA99602C2 (enExample)
WO (1) WO2008062063A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9499622B2 (en) 2014-02-18 2016-11-22 Samsung Electronics Co., Ltd. Anti-EGFR/anti-HER2 bispecific antibodies with anti-EGFR DARPins

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20080381B1 (ar) 2007-08-23 2023-03-28 Amgen Inc بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
US8187601B2 (en) 2008-07-01 2012-05-29 Aveo Pharmaceuticals, Inc. Fibroblast growth factor receptor 3 (FGFR3) binding proteins
WO2011053759A1 (en) * 2009-10-30 2011-05-05 Merck Sharp & Dohme Corp. Ax1 and ax189 pcsk9 antagonists and variants
US8790649B2 (en) * 2010-10-29 2014-07-29 Immunogen, Inc. EGFR-binding molecules and immunoconjugates thereof
EP2455403A1 (en) 2010-11-23 2012-05-23 Pierre Fabre Medicament Homogeneous humanized antibodies against JAM-A that inhibit proliferation
JOP20200043A1 (ar) 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
US20130287790A1 (en) * 2012-03-30 2013-10-31 The Board Of Trustees Of The Leland Standford Junior University Use of jam-a in diagnosing and treating leukemia
US9758591B2 (en) 2012-08-24 2017-09-12 The Regents Of The University Of California Antibodies and vaccines for use in treating ROR1 cancers and inhibiting metastasis
CN109071666B (zh) * 2016-03-01 2022-06-28 耶路撒冷希伯来大学伊森姆研究发展有限公司 人脊髓灰质炎病毒受体(pvr)特异性抗体
MX2018016330A (es) 2016-06-27 2020-02-17 Univ California Combinaciones para tratamiento del cáncer.
JP2019528311A (ja) 2016-08-03 2019-10-10 ネクストキュア インコーポレイテッド Ｌａｉｒシグナル伝達を調節するための組成物及び方法
CN109022366A (zh) * 2018-08-16 2018-12-18 江南大学 一株分泌抗左旋咪唑单克隆抗体的杂交瘤细胞株及其应用
JP7754506B2 (ja) 2019-10-08 2025-10-15 ネクチン セラピューティクス エルティーディー． ポリオウイルス受容体（ｐｖｒ）に対する抗体およびその使用
CN114740108B (zh) * 2022-03-28 2023-07-14 天津键凯科技有限公司 一种聚合物修饰抗体类药物的修饰度的测定方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9604470D0 (sv) * 1996-12-04 1996-12-04 Tamas Bartfai Konsulting Ab Transmembrane component of tight junction
US6235883B1 (en) * 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
US20030171568A1 (en) * 1998-09-16 2003-09-11 Avi Ashkenazi Use of A33 antigens and JAM-IT
AU752730B2 (en) * 1998-04-03 2002-09-26 Chugai Seiyaku Kabushiki Kaisha Humanized antibody against human tissue factor (TF) and process for constructing humanized antibody
EE05497B1 (et) * 1999-03-11 2011-12-15 Rmf Dictagene S.A. Polüpeptiid, lahustuv CRAM-1 polüpeptiid, polünukleotiid ja antikeha
WO2005060457A2 (en) * 2003-12-04 2005-07-07 Pdl Biopharma, Inc. Treatment of inflammatory bowel diseases with anti-ip-10 antibodies
WO2006008076A2 (en) * 2004-07-16 2006-01-26 Universita Degli Studi Di Milano Methods and agents stimulating the immune response
JP2008539693A (ja) * 2005-05-12 2008-11-20 オンコセラピー・サイエンス株式会社 抗ｄｓｃ２抗体のエフェクター機能を用いて細胞を障害する方法
US7981628B2 (en) * 2006-04-28 2011-07-19 Oregon Health & Science University Monoclonal antibodies and their use

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9499622B2 (en) 2014-02-18 2016-11-22 Samsung Electronics Co., Ltd. Anti-EGFR/anti-HER2 bispecific antibodies with anti-EGFR DARPins

Also Published As

Publication number Publication date
NZ576174A (en) 2012-03-30
IL198744A0 (en) 2010-02-17
CN101535344B (zh) 2013-10-16
AU2007324509B2 (en) 2013-01-17
CA2670039A1 (en) 2008-05-29
GT200900126A (es) 2011-09-02
FR2909092B1 (fr) 2012-10-19
JP2010509931A (ja) 2010-04-02
CL2007003357A1 (es) 2008-04-04
TN2009000194A1 (en) 2010-10-18
NO20092360L (no) 2009-08-11
UA99602C2 (ru) 2012-09-10
CN101535344A (zh) 2009-09-16
ECSP099341A (es) 2009-06-30
NI200900079A (es) 2010-11-10
CU23792A3 (es) 2012-03-15
MA30891B1 (fr) 2009-11-02
MX2009005293A (es) 2009-08-07
FR2909092A1 (fr) 2008-05-30
TW200829602A (en) 2008-07-16
WO2008062063A1 (en) 2008-05-29
SA07280637B1 (ar) 2012-04-11
RU2009123409A (ru) 2010-12-27
HK1132752A1 (en) 2010-03-05
GEP20125629B (en) 2012-09-10
US8071730B2 (en) 2011-12-06
BRPI0719323A2 (pt) 2014-02-04
CR10788A (es) 2009-06-23
US20120156191A1 (en) 2012-06-21
EP2074148A1 (en) 2009-07-01
AU2007324509A1 (en) 2008-05-29
RU2451689C2 (ru) 2012-05-27
US20100092455A1 (en) 2010-04-15

Similar Documents

Publication Publication Date Title
AU2007324509B2 (en) Novel antiproliferation antibodies
JP7531667B2 (ja) リンパ球における阻害経路の中和
KR101671039B1 (ko) 항 ｃｘｃｒ4 항체 및 그들의 암의 치료를 위한 용도
EP2535356B1 (en) Novel antibodies inhibiting C-MET dimerization, and uses thereof
CN101939336B (zh) Axl抗体
CN102421802B (zh) 人源化的axl抗体
MX2008000964A (es) Anticuerpos anti-receptor de factor de crecimiento similar a la insulina-i novedosos y usos de los mismos.
HK1132752B (en) Novel antiproliferation antibodies
HK40089230A (zh) 药物组合物及用途
AU2014200629A1 (en) Novel antibodies inhibiting c-met dimerization, and uses thereof
HK1163119B (en) Anti cxcr4 antibodies and their use for the treatment of cancer

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20090512

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20121120

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20140524

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20141223

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20140524

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I